5.80
-0.20 (-3.33%)
| Penutupan Terdahulu | 6.00 |
| Buka | 5.78 |
| Jumlah Dagangan | 84,980 |
| Purata Dagangan (3B) | 82,810 |
| Modal Pasaran | 126,104,208 |
| Harga / Pendapatan (P/E Ke hadapan) | 26.88 |
| Harga / Jualan (P/S) | 11.51 |
| Harga / Buku (P/B) | 3.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Mar 2026 |
| Margin Operasi (TTM) | -125.87% |
| EPS Cair (TTM) | -1.28 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.20% |
| Nisbah Semasa (MRQ) | 17.14 |
| Aliran Tunai Operasi (OCF TTM) | -7.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.74 M |
| Pulangan Atas Aset (ROA TTM) | -26.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Alpha Cognition Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 3.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 1.30 |
|
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.04% |
| % Dimiliki oleh Institusi | 44.14% |
| Julat 52 Minggu | ||
| Median | 18.00 (210.35%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Dec 2025 | 18.00 (210.34%) | Beli | 5.56 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 5.80 | - | 142,308 | 821,316 |
| Jumlah Keseluruhan Kuantiti Bersih | 142,308 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 821,316 | |||
| Purata Pembelian Keseluruhan ($) | 5.80 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 09 Mar 2026 | Beli (+) | 2,179 | 5.87 | 12,791 | |
| OPALEYE MANAGEMENT INC. | 06 Mar 2026 | Beli (+) | 1,900 | 5.79 | 11,001 | |
| OPALEYE MANAGEMENT INC. | 05 Mar 2026 | Beli (+) | 47,023 | 5.74 | 269,912 | |
| OPALEYE MANAGEMENT INC. | 04 Mar 2026 | Beli (+) | 19,795 | 5.86 | 115,999 | |
| OPALEYE MANAGEMENT INC. | 03 Mar 2026 | Beli (+) | 51,411 | 5.75 | 295,613 | |
| OPALEYE MANAGEMENT INC. | 02 Mar 2026 | Beli (+) | 20,000 | 5.80 | 116,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2026 | Pengumuman | Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |